US9996671B2 - Method for providing reliable non-invasive diagnostic tests - Google Patents

Method for providing reliable non-invasive diagnostic tests Download PDF

Info

Publication number
US9996671B2
US9996671B2 US14/413,445 US201314413445A US9996671B2 US 9996671 B2 US9996671 B2 US 9996671B2 US 201314413445 A US201314413445 A US 201314413445A US 9996671 B2 US9996671 B2 US 9996671B2
Authority
US
United States
Prior art keywords
data
index
reliability
score
initial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/413,445
Other languages
English (en)
Other versions
US20150205928A1 (en
Inventor
Paul Cales
Gilles Hunault
Jerome Boursier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite dAngers
Centre Hospitalier Universitaire dAngers
Original Assignee
Universite dAngers
Centre Hospitalier Universitaire dAngers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite dAngers, Centre Hospitalier Universitaire dAngers filed Critical Universite dAngers
Assigned to CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS, UNIVERSITE D'ANGERS reassignment CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOURSIER, JEROME, CALES, PAUL, Hunault, Gilles
Publication of US20150205928A1 publication Critical patent/US20150205928A1/en
Application granted granted Critical
Publication of US9996671B2 publication Critical patent/US9996671B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G06F19/345—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4222—Evaluating particular parts, e.g. particular organs
    • A61B5/4244—Evaluating particular parts, e.g. particular organs liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient ; user input means
    • A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G06F19/3431—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7221—Determining signal validity, reliability or quality
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Psychiatry (AREA)
  • Signal Processing (AREA)
US14/413,445 2012-07-13 2013-07-15 Method for providing reliable non-invasive diagnostic tests Active 2035-01-27 US9996671B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12176372 2012-07-13
EP12176372.6A EP2684513A1 (en) 2012-07-13 2012-07-13 Method for providing reliable non-invasive diagnostic tests
EP12176372.6 2012-07-13
PCT/EP2013/064954 WO2014009569A1 (en) 2012-07-13 2013-07-15 Method for providing reliable non-invasive diagnostic tests

Publications (2)

Publication Number Publication Date
US20150205928A1 US20150205928A1 (en) 2015-07-23
US9996671B2 true US9996671B2 (en) 2018-06-12

Family

ID=48793248

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/413,445 Active 2035-01-27 US9996671B2 (en) 2012-07-13 2013-07-15 Method for providing reliable non-invasive diagnostic tests

Country Status (7)

Country Link
US (1) US9996671B2 (zh)
EP (2) EP2684513A1 (zh)
JP (1) JP2015522173A (zh)
CN (1) CN104768448A (zh)
BR (1) BR112015000698A2 (zh)
ES (1) ES2685395T3 (zh)
WO (1) WO2014009569A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2739687C1 (ru) * 2020-04-03 2020-12-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ определения средней скорости образования фиброза печени у больных с хроническим гепатитом с

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104569396B (zh) * 2015-01-27 2018-02-23 北京唯尚立德生物科技有限公司 肝癌诊断试剂及其用途
US20190148004A1 (en) * 2015-04-07 2019-05-16 Universite D'angers Non-invasive method for assessing the presence and severity of esophageal varices
CN104887243B (zh) * 2015-07-02 2017-08-01 郭璐 一种血小板指数测评快查计算滑动尺
KR20180049098A (ko) * 2015-09-14 2018-05-10 장피트 비알코올성 지방간염을 진단 및 평가하는 방법
JP7007361B2 (ja) * 2016-08-01 2022-01-24 センター ホスピタリア ユニバーシタイア ダンガース 複数標的線維症検査
CN111816308B (zh) * 2020-07-13 2023-09-29 中国医学科学院阜外医院 一种通过面部图片分析预测冠心病发病风险的系统

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001086304A2 (en) 2000-04-28 2001-11-15 Bayer Aktiengesellschaft Diagnostic of liver fibrosis with serum marker algorithms
WO2004058055A2 (en) 2002-12-24 2004-07-15 Biosite Incorporated Method and system for disease detection using marker combinations
WO2005116901A2 (fr) 2004-05-14 2005-12-08 Universite D'angers Methode pour diagnostiquer la presence et/ou la severite d’une pathologie hepatique chez un sujet et/ou pour suivre l’efficacite d’un traitement d’une telle pathologie
WO2006009702A2 (en) 2004-06-15 2006-01-26 Bayer Healthcare Llc Liver disease-related methods and systems
WO2007130831A2 (en) 2006-05-01 2007-11-15 Provista Diagnostics, Llc Methods and apparatus for identifying disease status using biomarkers
WO2010013235A2 (en) 2008-07-29 2010-02-04 Exalenz Bioscience Ltd. Breath test device and method
WO2010097472A1 (en) 2009-02-26 2010-09-02 Universite D'angers Improved diagnosis of liver fibrosis or cirrhosis

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001086304A2 (en) 2000-04-28 2001-11-15 Bayer Aktiengesellschaft Diagnostic of liver fibrosis with serum marker algorithms
WO2004058055A2 (en) 2002-12-24 2004-07-15 Biosite Incorporated Method and system for disease detection using marker combinations
WO2005116901A2 (fr) 2004-05-14 2005-12-08 Universite D'angers Methode pour diagnostiquer la presence et/ou la severite d’une pathologie hepatique chez un sujet et/ou pour suivre l’efficacite d’un traitement d’une telle pathologie
WO2006009702A2 (en) 2004-06-15 2006-01-26 Bayer Healthcare Llc Liver disease-related methods and systems
CN1968601A (zh) 2004-06-15 2007-05-23 拜尔健康护理有限责任公司 与肝病相关的方法和系统
WO2007130831A2 (en) 2006-05-01 2007-11-15 Provista Diagnostics, Llc Methods and apparatus for identifying disease status using biomarkers
CN101479599A (zh) 2006-05-01 2009-07-08 曾罗维斯塔诊断学有限责任公司 使用生物标记鉴别疾病状态的方法和设备
WO2010013235A2 (en) 2008-07-29 2010-02-04 Exalenz Bioscience Ltd. Breath test device and method
WO2010097472A1 (en) 2009-02-26 2010-09-02 Universite D'angers Improved diagnosis of liver fibrosis or cirrhosis
CN102334122A (zh) 2009-02-26 2012-01-25 昂热大学 肝纤维化或肝硬化的改进诊断

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
Adams et al. "Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection" Clin. Chem., 2005, 51(10):1867-1873.
Boursier et al. "Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C" Eur. J. Gastroenterol. Hepatol., 2009, 21(1):28-38.
Cales et al. "A novel panel of blood markers to assess the degree of liver fibrosis" Hepatology, 2005, 42(6):1373-1381.
Cales et al. "Comparison of blood tests for liver fibrosis specific or not to NAFLD" J. Hepatol., 2009, 50(1):165-173.
Cales et al. "Optimization and robustness of blood tests for liver fibrosis and cirrhosis" Clin. Biochem., 2010, 43(16-17):1315-1322.
Cales, et al.; "Evaluating the Accuracy and Increasing the Reliable Diagnosis Rate of Blood Tests for Liver Fibrosis in Chronic Hepatitis C"; vol. 28, No. 10; May 20, 2008; pp. 1352-1362.
Castera et al. "Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C" Gastroenterology, 2005, 128(2):343-50.
Delong et al. "Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach" Biometrics, 1988, 44(3):837-845.
Friedrich-Rust et al. "Performance of transient elastography for the staging of liver fibrosis: a meta-analysis" Gastroenterology, 2008, 134(4):960-974.
Hanley et al. "The meaning and use of the area under a receiver operating characteristic (ROC) curve" Radiology, 1982, 143(1):29-36.
Imbert-Bismut et al. "Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study" Lancet, 2001, 357(9262):1069-1075.
International Search Report dated Nov. 19, 2013, corresponding to PCT/EP2013/064954.
Leroy et al. "Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C" J. Hepatol., 2007, 46(5):775-782.
Patel et al. "Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients" J. Hepatol., 2004, 41(6):935-942.
Rosenberg et al. "Serum markers detect the presence of liver fibrosis: a cohort study" Gastroenterology, 2004, 127(6):1704-1713.
Stebbing et al. "A meta-analysis of transient elastography for the detection of hepatic fibrosis" J. Clin. Gastroenterol., 2010, 44(3):214-219.
Vallet-Pichard et al. "FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest" Hepatology, 2007, 46(1):32-36.
Wai et al. "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C" Hepatology, 2003, 38(2):518-526.
Wang, et al.; "Identification of the Risk for Liver Fibrosis on CHB Patients Using Artificial Neural Network based on Routine and Serum Markers"; vol. 10, 251, Aug. 24, 2010; pp. 1-8.
Zarski et al. "Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study" J. Hepatol., 2012, 56(1):55-62.
Ziol et al. "Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C" Hepatology, 2005, 41(1):48-54.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2739687C1 (ru) * 2020-04-03 2020-12-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ определения средней скорости образования фиброза печени у больных с хроническим гепатитом с

Also Published As

Publication number Publication date
JP2015522173A (ja) 2015-08-03
WO2014009569A1 (en) 2014-01-16
EP2872031B1 (en) 2018-06-20
EP2684513A1 (en) 2014-01-15
ES2685395T3 (es) 2018-10-08
EP2872031A1 (en) 2015-05-20
BR112015000698A2 (pt) 2017-06-27
CN104768448A (zh) 2015-07-08
US20150205928A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
US9996671B2 (en) Method for providing reliable non-invasive diagnostic tests
Hagjer et al. Evaluation of the BISAP scoring system in prognostication of acute pancreatitis–A prospective observational study
Boursier et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography
CN103517668B (zh) 基于新的详细分类来评估肝纤维化的存在或严重度的无创性方法
Van Tho et al. A mixed phenotype of airway wall thickening and emphysema is associated with dyspnea and hospitalization for chronic obstructive pulmonary disease
CN106462666A (zh) 肝病的预诊检测
US10198552B2 (en) Method of diagnosis of fibrotic diseases
Wang et al. Leukocyte cell population data from the blood cell analyzer as a predictive marker for severity of acute pancreatitis
Blank et al. M probe comes first: Impact of initial probe choice on diagnostic performance of vibration controlled transient elastography
JP7007361B2 (ja) 複数標的線維症検査
Tsvetkov et al. Machine learning model for diagnosing the stage of liver fibrosis in patients with chronic viral hepatitis C
Cleveland et al. Clinical oral examinations may not be predictive of dysplasia or oral squamous cell carcinoma
WO2022025069A1 (ja) 疾患リスク評価方法、疾患リスク評価装置、及び疾患リスク評価プログラム
Li et al. Development and validation of a routine blood parameters-based model for screening the occurrence of retinal detachment in high myopia in the context of PPPM
RU2557927C1 (ru) Способ диагностики фиброза печени при хроническом вирусном гепатите с
EP4022302A1 (en) Algorithm for the identification and phenotyping of nonalcoholic fatty liver disease patients
Waldén et al. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study
Atzori et al. The accuracy of ultrasound Controlled Attenuation Parameter in diagnosing hepatic fat content
Oh et al. Monocyte Distribution Widths for Early Sepsis Detection in Emergency Department and Comparison with C-reactive Protein and Procalcitonin
Zhuo et al. CT measurements of optic nerve sheath diameter to evaluate the outcome of acute carbon monoxide poisoning
Xie et al. LiveBoost: A GB-based prediction system for liver fibrosis in chronic hepatitis B patients in China-A multi-center retrospective study
Buckholz et al. Noninvasive Fibrosis Testing in Chronic Liver Disease Including Caveats
Xu et al. The predictive value of three risk score scales for postoperative pulmonary complications in critically ill patients: A retrospective cohort study
Elghmary et al. Comparative Study between Fibro-Test and Egy-Score as Non-Invasive Markers for Assessment of Hepatic Fibrosis in Chronic Hepatitis C
KR20220076778A (ko) 간섬유증의 비침습적 진단용 미토콘드리아 바이오마커 및 이의 용도

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CALES, PAUL;HUNAULT, GILLES;BOURSIER, JEROME;SIGNING DATES FROM 20150309 TO 20150316;REEL/FRAME:036022/0706

Owner name: UNIVERSITE D'ANGERS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CALES, PAUL;HUNAULT, GILLES;BOURSIER, JEROME;SIGNING DATES FROM 20150309 TO 20150316;REEL/FRAME:036022/0706

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4